CClinicalTrials.gg
Sign In
Status unknownNCT01482585Updated Nov 30, 2011

Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy

An observational study in Lung Adenocarcinoma, sponsored by Samsung Medical Center. Status unknown at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2011-11-30.

Sponsored by Samsung Medical Center · Observational

The sponsor has not verified this record recently (last verified Nov 2011), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
200
Ages
20 Years and older
Sex
All
01

Study summary

to determine the values of imaging and genetic biomarkers for prediction of tumor aggressiveness and prognosis in patient with early stage lung adenocarcinoma to Identify unique copy number alteration in patient with early stage lung adenocarcinoma to evaluate the long-term change of ground-glass nodule combined with lung adenocarcinoma to suggest a guideline for planning an appropriate follow-up examination and management

02

Conditions studied

  • Lung Adenocarcinoma

Keywords

  • lung adenocarcinoma
  • prognosis
  • tumor aggressiveness
  • imaging biomarker
  • genetic biomarker
03

In context

Adenocarcinoma

2,004 studies on the registry are indexed under Adenocarcinoma; 375 are open to participants now.

This study's planned enrollment of 200 is above the median of 153 across 332 observational studies indexed under Adenocarcinoma.

Browse Adenocarcinoma studies →

Lead sponsor

Samsung Medical Center is the lead sponsor of 980 studies on the registry; 146 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients with stage I or II lung adenocarcinoma who plans curative operation

Inclusion criteria

  • A. Clinically and radiologically suspected lung adenocarcinoma
  • B. Newly-diagnosed Stage I or II from the clinical work up including PET/CT
  • C. Performance status of 0 to 1 on the ECOG scale
  • D. Age 20 years or older
  • E. Able to tolerable DECT imaging required by protocol
  • F. Able to give study-specific informed consent

Exclusion criteria

Exclusion Criteria:

  • A. Prior malignancy
  • B. planning of Definitive RTx 나 neoadjuvant CCRTx
  • C. Poor cardiopulmonary reserve
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
200 participants (estimated)
Biospecimen retention
Samples with dna

Groups and cohorts

  • early stage lung adenocarcinoma

    Other: CT, PET, copy number alteration

Interventions

  • OtherCT, PET, copy number alteration

    Duel-energy CT, PET, copy number alteration

06

What researchers measure

Primary outcomes

  1. Prediction of tumor aggressiveness

    Time frame: five years

Secondary outcomes

  1. prognosis of early stage lung adenocarcinoma following operation

    Time frame: five years

07

Study locations

1 of 1 sites recruiting
  • Samsung Medical Center
    Seoul, Korea, Republic of
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 30, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01482585
Lead sponsor
Samsung Medical Center
Collaborators
Korean Foundation for Cancer Research
Responsible party
Sponsor
First posted
Nov 30, 2011
Start date
Oct 2011
Primary completion
Jul 2016 (estimated)
Completion
Dec 2016 (estimated)
Last update
Nov 30, 2011

Study contacts

Young Mog Shim, Dr.
Contact
youngmog.shim@samsung.com
Ho Yun Lee, Dr.
Contact
hoyunlee96@gmail.com
Young Mog Shim, Dr.
principal investigator · Samsung Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Adenocarcinoma→

Other studies from this sponsor

Samsung Medical Center

Start the discussion